Denali Therapeutics Inc. [DNLI] Insider Activity: An Update for Investors


Denali Therapeutics Inc.’s recently made public that its Chief Medical Officer Ho Carole unloaded Company’s shares for reported $58561.0 on Aug 23. In the deal valued at $23.22 per share,2,522 shares were sold. As a result of this transaction, Ho Carole now holds 182,809 shares worth roughly $ 4.36 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Schuth Alexander O. sold 2,522 shares, generating $58,435 in total proceeds. Upon selling the shares at $23.17, the COFO and Secretary now owns 518,989 shares.

Before that, Ho Carole sold 2,478 shares. Denali Therapeutics Inc. shares valued at $56,003 were divested by the Chief Medical Officer at a price of $22.60 per share. As a result of the transaction, Ho Carole now holds 185,331 shares, worth roughly $4.42 million.

SVB Securities initiated its Denali Therapeutics Inc. [DNLI] rating to an Outperform in a research note published on Tuesday, January 30, 2023; the price target was $50. PT values the company’s stock at a premium of 52.32 to its Tuesday closing price.

Price Performance Review of DNLI

On Tuesday, Denali Therapeutics Inc. [NASDAQ:DNLI] saw its stock jump 2.27% to $23.84. On the same session, the stock had its day’s lowest price of $23.27, but rose to a high of $24.21. Over the last five days, the stock has gained 4.70%. Denali Therapeutics Inc. shares have fallen nearly -14.28% since the year began. Nevertheless, the stocks have fallen -14.80% over the past one year. While a 52-week high of $34.78 was reached on 06/16/23, a 52-week low of $21.74 was recorded on 03/30/23. SMA at 50 days reached $26.69, while 200 days put it at $27.75. A total of 0.95 million shares were traded, compared to the trading of 0.56 million shares in the previous session.

Levels Of Support And Resistance For DNLI Stock

The 24-hour chart illustrates a support level at 23.34, which if violated will result in even more drops to 22.83. On the upside, there is a resistance level at 24.28. A further resistance level may holdings at 24.71. The Relative Strength Index (RSI) on the 14-day chart is 43.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 28.14%. Stochastics %K at 57.66% indicates the stock is a holding.

How much short interest is there in Denali Therapeutics Inc.?

A steep rise in short interest was recorded in Denali Therapeutics Inc. stocks on Aug 14, 2023, growing by 1.06 million shares to a total of 9.23 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 8.17 million shares. There was a rise of 11.48%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 7.98% of the overall stock float, the days-to-cover ratio (short ratio) rose to 17.74.

Denali Therapeutics Inc. [DNLI] – Who Are The Largest Shareholders?

In filings from Baillie Gifford & Co., it is revealed that the company now owns 14,843,770 shares, or roughly 10.84% of the outstanding DNLI shares. In other words, the investor’s shares have fallen by -508,341 from its previous 13-F filing of 15352111.0. Additionally, The Vanguard Group, Inc. increased 0.91% of its stake after which the total value it holdings stand at $282,025,344, while BlackRock Fund Advisors added 7.42% of its stake to hold $233.71 million in the firm. Over the last quarter, Wellington Management Co. LLP purchased 1,837,716 shares of Denali Therapeutics Inc., while Temasek Holdings Pte Ltd. bought 0 shares. At present, Crestline Management LP is holding 6,110,732 shares valued at $173.73 million. SSgA Funds Management, Inc. owned 4,468,491 shares of the company at the time of its most recent 13F filing, worth $127.04 million.

According to FactSet, Denali Therapeutics Inc.’s share price will average $54.57 in the next year, based on opinions of analysts polled by the firm. This is up nearly 123.08 percent from its previous closing price of $23.31. Analysts expect Denali Therapeutics Inc. stock to reach the higher price of $105.00, while the lowest price estimate is $26.00. However, 16 analysts have rated DNLI stock as a Buy in their predictions for 2023.


Please enter your comment!
Please enter your name here